Nirmal Bang

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

A Relationship Beyond Broking

External broker reports(aggregated public sources), Nirmal Bang

External broker reports(aggregated public sources)

Equity Bottom-Up

Zydus Lifesciences Ltd / Equity Bottom-Up

<div><ul><li>Mesalamine Portfolio: In the US market, Zydus faced competition and price erosion in gLialda while the company continues to be the sole generic player in Asacol HD. </li></ul><div><ul><li>In May’22, Sun Pharma was the first generic player to receive final USFDA approval for gPentasa.</li></ul><div><ul><li>We expect Zydus to <span style="font-size: var(--content-font-size);">also receive an approval for gPentasa soon.</span></li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Mesalamine Portfolio: In the US market, Zydus faced competition and price erosion in gLialda while the company continues to be the sole generic player in Asacol HD. In May’22, Sun Pharma was the first generic player to receive final USFDA approval for gPentasa.We expect Zydus to also receive an approval for gPentasa soon.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Zydus Lifesciences - Excluding One-Offs, Earnings In-Line with Estimates